Suppression of ovulation by a new subcutaneous depot medroxyprogesterone acetate (104 mg/0.65 ml) contraceptive formulation in asian women

Clinical Therapeutics

Volumn 26, Issue 11, 2004, Pages 1845-1854

  Cheng Toh, Yeong ^a   Jain, John ^b   Rahnny, Mohamad H ^c   Bode, Frederick R ^c   Ross, Doug ^c  

^a KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c PFIZER INC   (United States)

Author keywords

depot medroxyprogesterone acetate 104 mg 0.65 mL nondaily contraception subcutaneous injection ovulation suppression

Indexed keywords

ESTRADIOL; FOLLITROPIN; LUTEINIZING HORMONE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

ABDOMEN; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; ESTRADIOL BLOOD LEVEL; ETHNOLOGY; FEMALE; FLU LIKE SYNDROME; FOLLITROPIN BLOOD LEVEL; HEADACHE; HORMONAL CONTRACEPTION; HORMONE DETERMINATION; HUMAN; HUMAN EXPERIMENT; INJECTION SITE; LUTEINIZING HORMONE BLOOD LEVEL; MEDICAL ASSESSMENT; MIGRAINE; OUTPATIENT CARE; OVULATION INHIBITION; PROGESTERONE BLOOD LEVEL; SINGLE DRUG DOSE; THIGH;

ADULT; AMBULATORY CARE; ASIAN CONTINENTAL ANCESTRY GROUP; CONTRACEPTIVE AGENTS, FEMALE; DELAYED-ACTION PREPARATIONS; ESTRADIOL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MEDROXYPROGESTERONE 17-ACETATE; OVULATION; PROGESTERONE; SINGAPORE; TIME FACTORS;

EID: 11844278316     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2004.11.013     Document Type: Article

References (16)

1. Kaunitz A.M. Injectable contraception. New and existing options Obstet Gynecol Clin North Am 27 2000 741 780
2. Trussell J. Contraceptive failure in the United States Contraception 70 2004 89 96
3. Mishell D.R. Jr Pharmacokinetics of depot medroxyprogesterone acetate contraception J Reprod Med 41 Suppl 5 1996 381 390
4. Henshaw S.K. Unintended pregnancy in the United States Fam Plann Perspect 30 1998 24 29
5. Henshaw S.K. Unintended pregnancy in the United States Fam Plann Perspect 30 1998 46
6. Piccinino L.J., and Mosher W.D. Trends in contraceptive use in the United States: 1982-1995 Fam Plann Perspect 30 1998 4 10
7. Piccinino L.J., and Mosher W.D. Trends in contraceptive use in the United States: 1982-1995 Fam Plann Perspect 30 1998 46
8. Fulfilling the Promise.' Public Policy and U.S. Family Planning Clinics 2000 Alan Guttmacher Institute New York
9. Garza-Flores J., Rodriguez V., and Perez-Palacios G. World Health Organization Task Force on Long Acting Systemic Agents for Fertility Regulation A multicentered pharmacokinetic, pharmacodynamic study of once-a-month injectable contraceptives. I. Different doses of HRP112 and of DepoProvem Contraception 36 1987 441 457
10. Prepelitskaya G.V., Zhang Z.P., and Pearsall A.B. Validation Report LCMSC198: Quantitation of MPA in Human Serum via HPLC with MS/MS Detection 2001 Pharmaceutical Product Development Richmond, Va
11. Pearsall A.B., Serafin R.J., and Walton S.W. LC/MS/MS Analysis of Medroxyprogesterone Acetate in Human Serum. Project YBK 2002 Pharmaceutical Product Development Richmond, Va
12. Available at Pharmaceutical Product Development List of validated methods Accessed August 19, 2004
13. Gibaldi M., and Perrier D. Noncompartmental analysis based on statistical moment theory Pharmacokinetics 2nd ed 1982 Marcel Dekker New York 409 417
14. Jain J., Dutton C., and Nicosia A. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo Provera Contraception 70 2004 11 18
15. Lobo R.A. Progestogen metabolism J Reprod Med 44 Suppl 2 1999 148 152
16. Jain J., Jakimiuk A.J., and Bode F.R. Contraceptive efficacy and safety of DMPA-SC Contraception 70 2004 269 275